Sitagliptin and Interstitial lung disease - a phase IV clinical study of FDA data

Summary:

Interstitial lung disease is reported as a side effect among people who take Sitagliptin (sitagliptin), especially for people who are male, 60+ old, have been taking the drug for 6 - 12 months also take Metformin, and have Diabetes.

The phase IV clinical study analyzes which people have Interstitial lung disease when taking Sitagliptin. It is created by eHealthMe based on reports of 3,929 people who have side effects when taking Sitagliptin from the FDA, and is updated regularly.

What is Sitagliptin?

Sitagliptin has active ingredients of sitagliptin. eHealthMe is studying from 3,933 Sitagliptin users. Check the latest studies of Sitagliptin.

What is Interstitial lung disease?

Interstitial lung disease is found to be associated with 1,500 drugs and 1,839 conditions by eHealthMe. Check the latest studies of Interstitial lung disease.

On Jul, 12, 2026

3,929 people reported to have side effects when taking Sitagliptin.
Among them, 40 people (1.02%) have Interstitial lung disease.

Could Sitagliptin cause Interstitial lung disease?

Among these 40 people:

How long have people been on Sitagliptin when they have Interstitial lung disease? *

What is the gender of people who have Interstitial lung disease when taking Sitagliptin? *

female: 5.41 %
male: 94.59 %

What is the age of people who have Interstitial lung disease when taking Sitagliptin? *

What are other drugs people take besides Sitagliptin? *

Metformin: 16 people, 40.00%
Opdivo: 15 people, 37.50%
Crestor: 10 people, 25.00%
Xarelto: 10 people, 25.00%
Paclitaxel: 10 people, 25.00%
Metformin Hydrochloride: 9 people, 22.50%
Allopurinol: 7 people, 17.50%
Torsemide: 6 people, 15.00%
Bisoprolol Fumarate: 6 people, 15.00%
Lorazepam: 6 people, 15.00%

What are other side effects people have besides Interstitial lung disease? *

Cough: 4 people, 10.00%
Nasopharyngitis (inflammation of the nasopharynx): 3 people, 7.50%
Lymphangiosis Carcinomatosa (inflammation of the lymph vessels can lead to cancer): 2 people, 5.00%
Dyspnea (difficult or laboured breathing): 2 people, 5.00%
Rashes (redness): 2 people, 5.00%
Pulmonary Embolism (blockage of the main artery of the lung): 2 people, 5.00%
Pneumonia Bacterial (pneumonia associated with bacterial infection): 2 people, 5.00%
Malaise (a feeling of general discomfort or uneasiness): 2 people, 5.00%
Renal Disorder (kidney disease): 2 people, 5.00%
C-Reactive Protein Increased: 1 person, 2.50%

What are the existing conditions these people have? *

Diabetes: 21 people, 52.50%
Type 2 Diabetes: 11 people, 27.50%
Ventricular Tachycardia (rapid heartbeat that originates in one of the lower chambers (the ventricles) of the heart): 10 people, 25.00%
Nasal Sinus Cancer (cancer of hollow cavity behind nose): 10 people, 25.00%
High Blood Pressure: 9 people, 22.50%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 7 people, 17.50%
Sleep Disorder: 6 people, 15.00%
Cardiac Failure: 6 people, 15.00%
Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 3 people, 7.50%
Hepatocellular Carcinoma (liver cancer): 3 people, 7.50%

* Approximation only. Some reports may have incomplete information.

Do you take Sitagliptin and have Interstitial lung disease?

- Check whether Interstitial lung disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sitagliptin:

Sitagliptin (3,933 reports)

Browse all side effects of Sitagliptin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Interstitial lung disease:

Interstitial lung disease (1,500 drugs)

Browse all the conditions that are associated with Interstitial lung disease:

Interstitial lung disease (1,839 conditions)

Related publications that referenced our studies

Thangakunam B, Christopher DJ, Mathews V, Srivastava A, "Mesenchymal stromal stem cell therapy in advanced interstitial lung disease-Anaphylaxis and short-term follow-up", Lung India: official organ of Indian Chest Society, 2015 Jan .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .
Thangakunam B, Christopher DJ, Mathews V, Srivastava A, "Mesenchymal stromal stem cell therapy in advanced interstitial lung disease-Anaphylaxis and short-term follow-up", Lung India: official organ of Indian Chest Society, 2015 Jan .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on sitagliptin (the active ingredients of Sitagliptin) and Sitagliptin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.